Amarin's Fish Oil Pill Faces Even More Exclusivity Risks

I was speaking with an institutional investor last week who made money on Amarin when Vascepa was still in clinical development and known as AMR101.

http://www.thestreet.com/story/11901372/1/amarins-fish-oil-pill-faces-even-more-exclusivity-risks.html?cm_ven=RSSFeed